(Core C) Core C (Biostatistics) is a new Research Support Core in the revised application and will be led by Dr. Paul Wileyto. In the previous application, the Biostatistics services were included under Core A (Administrative Core). This Program Project tests hypotheses related to the idea that Integrated Stress Response (ISR) mediates MYC-dependent and hypoxia-dependent tumor progression. The observables directly resulting from in-vitro and in-vivo experiments include direct observation of tumor cell death, tumor cell survival and growth, latency to tumor formation, and host survival. These outcomes are easily approached by standard statistical procedures that have been developed for laboratory and clinical studies.
The Aims of this new Biostatistics Core in the proposed funding period are:
Aim 1. To provide Biostatistics support to the all Project Leaders and co-Leaders in the following areas: a) Design of studies involving in-vitro and in-vivo experiments that do not fall under the umbrella of metabolomics and bio informatics.
Aim 2. To perform Statistical modeling and Statistical analysis to evaluate each project's research hypotheses.
Aim 3. To interpret research data and collaboration with investigators to make scientifically and statistically appropriate statements, and to also provide assistance in the preparation of scientific abstracts, presentations, and manuscripts.

Public Health Relevance

(CORE C) The overall goal of Core C is to interact with all project Leaders and their lab members on study design, data analysis and data interpretation as well as to evaluate methods related to quantification and data analysis to ensure rigor and reproducibility in the studies performed under this Program Project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA165997-07
Application #
10017918
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2013-09-18
Project End
2024-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Bu, Yiwen; Yoshida, Akihiro; Chitnis, Nilesh et al. (2018) A PERK-miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival. Nat Cell Biol 20:104-115
Nguyen, Hao G; Conn, Crystal S; Kye, Yae et al. (2018) Development of a stress response therapy targeting aggressive prostate cancer. Sci Transl Med 10:
Zhao, Bin; Bhattacharya, Sabyasachi; Yu, Qiujing et al. (2018) Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia. Leuk Lymphoma 59:171-177
Hong, Feng; Liu, Bei; Wu, Bill X et al. (2017) CNPY2 is a key initiator of the PERK-CHOP pathway of the unfolded protein response. Nat Struct Mol Biol 24:834-839
Rozpedek, W; Nowak, A; Pytel, D et al. (2017) Molecular Basis of Human Diseases and Targeted Therapy Based on Small-Molecule Inhibitors of ER Stress-Induced Signaling Pathways. Curr Mol Med 17:118-132
Ortiz, Angélica; Fuchs, Serge Y (2017) Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer. Cytokine 89:4-11
Katlinski, Kanstantsin V; Gui, Jun; Katlinskaya, Yuliya V et al. (2017) Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell 31:194-207
Davar, Diwakar; Fuchs, Serge Y; Kirkwood, John M (2016) BRAF Inhibitors and IFN?: Plus, Minus, or Indeterminate? J Natl Cancer Inst 108:
Bu, Yiwen; Diehl, J Alan (2016) PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development. J Cell Physiol 231:2088-96
Gui, Jun; Gober, Michael; Yang, Xiaoping et al. (2016) Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation. J Invest Dermatol 136:1990-2002

Showing the most recent 10 out of 28 publications